MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
It is the generic version of molnupiravir
It has also been granted permission to conduct trials for booster dose
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Partnering to build biosynthesis processes and a pharmaceutical production platform
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Subscribe To Our Newsletter & Stay Updated
